Sugi Predict

Sugi Predict / Compounds / SCHEMBL31072729

SCHEMBL31072729

SCHEMBL31072729

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C

nearest known ligand 0.81

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 20/20 0.81
▸ ECE1 P42892 1/20 0.75
▸ MUS81 Q96NY9 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29363146 0.99 GLP1R (0.83) GLP1RECE1MUS81
SCHEMBL27827907 0.99 GLP1R (0.83) GLP1RECE1MUS81
SCHEMBL30721588 0.99 GLP1R (0.83) GLP1RECE1MUS81
SCHEMBL29823404 0.99 GLP1R (0.83) GLP1RECE1MUS81
SCHEMBL29359146 0.99 GLP1R (0.83) GLP1RECE1MUS81
SCHEMBL29942457 0.99 GLP1R (0.83) GLP1RECE1MUS81
SCHEMBL29362765 0.99 GLP1R (0.83) GLP1RECE1MUS81
SCHEMBL31731011 0.99 GLP1R (0.83) GLP1RECE1MUS81
SCHEMBL30518507 0.98 GLP1R (0.83) GLP1RECE1MUS81
SCHEMBL30721547 0.98 GLP1R (0.83) GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12350320-B2 Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereof I2O THERAPEUTICS, INC. (US) 2025-07-08 — — US disclosed
US-12337029-B2 Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof I2O THERAPEUTICS, INC. (US) 2025-06-24 — — US disclosed
US-20250161415-A1 METHOD OF TREATING DISEASE OR DISORDER USING COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS I2O THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250144180-A1 COMPOSITIONS COMPRISING THERAPEUTIC PROTEINS OR PEPTIDES, AND USES THEREOF I2O THERAPEUTICS, INC. 2025-05-08 — — US disclosed
US-12233112-B2 Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof I20 THERAPEUTICS, INC. (US) 2025-02-25 — — US disclosed
US-12233110-B2 Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof I20 THERAPEUTICS, INC. (US) 2025-02-25 — — US disclosed
US-12233111-B2 Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof I2O THERAPEUTICS, INC. (US) 2025-02-25 — — US disclosed
US-20240336668-A1 IONIC LIQUID COMPOSITIONS I2O THERAPEUTICS, INC. 2024-10-10 — — US disclosed
US-20240325323-A1 IONIC LIQUID COMPOSITIONS I2O THERAPEUTICS, INC. 2024-10-03 — — US disclosed
US-20240307499-A1 IONIC LIQUID COMPOSITIONS I2O THERAPEUTICS, INC. 2024-09-19 — — US disclosed
US-20240293552-A1 IONIC LIQUID COMPOSITIONS I2O THERAPEUTICS, INC. 2024-09-05 — — US disclosed
US-20240277814-A1 IONIC LIQUID COMPOSITIONS I2O THERAPEUTICS, INC. 2024-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12337029-B2 Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof IAPP, GLP1R, GPR119 GLP1R 2/4885ECE1 789/4885MUS81 4020/4885
US-20240293552-A1 IONIC LIQUID COMPOSITIONS IAPP, IGF2BP3, IGFBP1 GLP1R 684/4885ECE1 2782/4885MUS81 4555/4885
US-20240325323-A1 IONIC LIQUID COMPOSITIONS IAPP, IGF2BP3, IGFBP1 GLP1R 684/4885ECE1 2782/4885MUS81 4555/4885
US-12233110-B2 Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof GLP1R, IAPP, SLC5A1 GLP1R 1/4885ECE1 1824/4885MUS81 4400/4885
US-12350320-B2 Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and pharmaceutically acceptable salts of amylin analogs, and uses thereof IAPP, GLP1R, GIPR GLP1R 2/4885ECE1 943/4885MUS81 4547/4885
US-12233112-B2 Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof IAPP, GLP1R, GPR119 GLP1R 2/4885ECE1 767/4885MUS81 3932/4885
US-12233111-B2 Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof GLP1R, IAPP, GCG GLP1R 1/4885ECE1 1721/4885MUS81 4311/4885
US-20240336668-A1 IONIC LIQUID COMPOSITIONS IAPP, IGF2BP3, IGFBP1 GLP1R 684/4885ECE1 2782/4885MUS81 4555/4885
US-20250161415-A1 METHOD OF TREATING DISEASE OR DISORDER USING COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS IAPP, INSR, GLP1R GLP1R 3/4885ECE1 903/4885MUS81 3982/4885
US-20250144180-A1 COMPOSITIONS COMPRISING THERAPEUTIC PROTEINS OR PEPTIDES, AND USES THEREOF IAPP, FABP4, FABP1 GLP1R 97/4885ECE1 1654/4885MUS81 4021/4885
US-20240307499-A1 IONIC LIQUID COMPOSITIONS IAPP, IGF2BP3, IGFBP1 GLP1R 684/4885ECE1 2782/4885MUS81 4555/4885
US-20240277814-A1 IONIC LIQUID COMPOSITIONS IAPP, IGF2BP3, IGFBP1 GLP1R 684/4885ECE1 2782/4885MUS81 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback